CORDIS
EU research results

CORDIS

English EN

A Modular Nanosystems Platform for Advanced Cancer Management: Nano-vehicles; Tumor Targeting and Penetration Agents; Molecular Imaging, Degradome based Therapy

Project information

Grant agreement ID: 263307

Status

Closed project

  • Start date

    1 March 2011

  • End date

    28 February 2015

Funded under:

FP7-NMP

  • Overall budget:

    € 13 809 085,64

  • EU contribution

    € 10 500 000

Coordinated by:

TEL AVIV UNIVERSITY

Israel

Objective

SaveMe project will address current urgent needs for pancreatic cancer diagnosis and treatment by exploiting partners’ expertise and most recent research achievements for the design and development of novel modular nanosystems platform integrating new functionalized nano-core particles and active agents. The modular platform will enable the design of diverse active nanosystems per diagnostic or therapeutic application as defined by their active agent compositions. For diagnostics, superior tracers will be developed for molecular MR/PET and gamma camera imaging, enabling efficient diagnosis and guided surgery respectively. Novel functionalized nano-core systems will be conjugated with semi-confluent active shell layer. Three types of shell layers will be design: (1) novel iron oxide nanoparticles as advanced MRI contrast agents and/or (2) DOTA complexes for MRI (with Gd3+), or PET (with Ga-68), or gamma camera (with Ga-69); (3) Integrating within one tracer both iron oxide nanoparticles and DOTA-Ga-68 complexes for a sequential or simultaneous MR/PET imaging. For therapeutics, active nanosystems will be developed to deliver (1) therapeutic siRNAs or (2) anti-MP-inhibitory-scFVs. These non-classic anti-tumor drugs will be designed based on an extensive tumor degradome analysis for combining blockage of selective matrix MPs, thus preventing basic invasive and metastasis steps, with siRNA based neutralization of secondary molecular effects induced by the specific protease inhibition. Individualized degradome analysis will be developed for potential profiling of anti-MP and siRNAs based therapy per patient. To facilitate the above diagnostics and therapeutic effects, advanced tumor targeting and penetration active agents will be linked to nano-core functionalized groups, including a biocompatible PEG layer linked to tumor selective MMP substrate molecules and highly safe and potent novel somatostatin analogue peptides targeting SSTR overexpression.

Coordinator

TEL AVIV UNIVERSITY

Address

Ramat Aviv
69978 Tel Aviv

Israel

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 842 728

Administrative Contact

Lea Pais (Ms.)

Participants (22)

VEREIN ZUR FOERDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG AM WILHELMINENSPITAL DER STADT WIEN

Austria

EU Contribution

€ 229 064

UNIVERSITATSKLINIKUM HEIDELBERG

Germany

EU Contribution

€ 967 806

BAR ILAN UNIVERSITY

Israel

EU Contribution

€ 1 123 440

ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA

Italy

EU Contribution

€ 461 600

JOHANN WOLFGANG GOETHE-UNIVERSITATFRANKFURT AM MAIN

Germany

EU Contribution

€ 252 748

RESEARCH AND PRODUCTION COMPLEX NANOSYSTEM LLC

Russia

EU Contribution

€ 165 200

FUNDACION CIDETEC

Spain

EU Contribution

€ 553 020

ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNE

Spain

EU Contribution

€ 584 000

COLOROBBIA ITALIA SPA

Italy

EU Contribution

€ 56 451

MEDICAL RESEARCH INFRASTRUCTURE DEVELOPMENT AND HEALTH SERVICES FUND BY THE SHEBA MEDICAL CENTER

Israel

EU Contribution

€ 873 865

UNIVERSITY OF EAST ANGLIA

United Kingdom

EU Contribution

€ 504 200

KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN

Germany

EU Contribution

€ 630 670

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

EU Contribution

€ 470 236

WEIZMANN INSTITUTE OF SCIENCE

Israel

EU Contribution

€ 601 107

SHEMYAKIN AND OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY - RUSSIAN ACADEMY OF SCIENCE

Russia

EU Contribution

€ 560 636

nHance Technologies Limited

United Kingdom

EU Contribution

€ 359 023

FILARETE SERVIZI SRL

Italy

EU Contribution

€ 356 800

GEMS PET SYSTEMS AB

Sweden

EU Contribution

€ 40 162

OSM-DAN LTD

Israel

EU Contribution

€ 381 640

BENCAR AB

Sweden

EU Contribution

€ 338 496

ASCEND TECHNOLOGIES LIMITED

United Kingdom

EU Contribution

€ 133 578

COLOROBBIA CONSULTING SRL

Italy

EU Contribution

€ 13 530

Project information

Grant agreement ID: 263307

Status

Closed project

  • Start date

    1 March 2011

  • End date

    28 February 2015

Funded under:

FP7-NMP

  • Overall budget:

    € 13 809 085,64

  • EU contribution

    € 10 500 000

Coordinated by:

TEL AVIV UNIVERSITY

Israel